secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001193125-25-303162
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences appoints Bhavesh Ashar as COO; Bensen becomes Chief Discovery Officer
--------------------------------------------------------------------------------

- Bhavesh Ashar appointed COO effective Dec 1, 2025; Daniel Bensen moved to Chief Discovery Officer.
- Ashar base salary $550,000; target annual incentive 40% of base.
- Granted options to purchase 300,000 shares vesting over 4 years (25% cliff at 1 year).
- Severance provisions: 12 months salary plus target bonus if terminated without cause outside change in control.
- Ashar previously Chief Commercial Officer at SpringWorks Therapeutics (Merck KGaA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525303162/0001193125-25-303162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312525303162/d57660d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-303162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer